Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

Wegovy's launch in Thaliand comes nearly a month after Eli Lilly launched its obesity management drug Mounjaro in India at ...

The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

A new paper evaluating Neuromod’s tinnitus treatment has found that 91.5% of patients saw reductions after 12 weeks of ...

The CEO of Novo Holdings has warned that his $160 billion fund will slow down investment activity until the dust settles ...

De Novo's cloud services operate out of three availability zones: a Frankfurt data center in Germany, and two data centers in ...

COVID-19 in children and adolescents is associated with adverse long-term kidney outcomes, such as chronic kidney disease (CKD).

Analysis found 25% tariff on pharmaceutical imports would hike U.S. drug costs by nearly $51 billion annually, boosting ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide ...

Todd Engel claims Ozempic caused his blindness. Lawsuit says Novo Nordisk failed to warn of rare vision risks.

Paralelno s razvojem vlastitih proizvoda, tvrtka je kontinuirano ulagala u startupe čije su misije usklađene s njezinim vrijednostima, kao i u razvoj internih tehnoloških rješenja koja su dodatno ...